Head-to-head evidence
HPP737 vs PF-07038124
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: PDE4 · full Psoriasis pipeline
HPP737
Developed by Newsoara Biopharma
NCT07712731 · Phase 3 · completed
The trial randomized 607 participants to HPP737 or active treatment with apremilast and used triple masking of participants, care providers, and investigators. Its primary endpoints were clinical psoriasis measures, but the treatment comparison cannot yet be judged because the registry has not posted results.
PF-07038124
Developed by Pfizer
NCT05375955 · Phase 2 · completed
This was a randomized, quadruple-blind, vehicle-controlled Phase 2 trial with a hard clinical primary endpoint (IGA/PGA response at week 12) and an adequate sample size (263 participants). However, the primary comparison was only partly successful: in atopic dermatitis, neither PF-07038124 0.01% (23.8% vs 11.4%, p=0.0711) nor 0.03% (21.4% vs 11.4%, p=0.1290) reached statistical significance, while in plaque psoriasis the 0.03% (37.1% vs 8.8%, p=0.0028) and 0.06% (45.5% vs 8.8%, p=0.0003) doses did. Because the primary endpoint was split across two diseases and only one cohort met it, the overall result is mixed rather than a clean success, capping the evidence at moderate.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HPP737's landscape · PF-07038124's landscape